Europe Monoclonal Antibodies Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Source (Human, Humanized, Chimeric, and Murine), Production Method (In-Vitro, and In-Vivo), Indication (Cancer, Autoimmune Diseases, Infectious Diseases, Infla

Europe Monoclonal Antibodies Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Source (Human, Humanized, Chimeric, and Murine), Production Method (In-Vitro, and In-Vivo), Indication (Cancer, Autoimmune Diseases, Infectious Diseases, Inflammatory Diseases, Microbial Diseases, and Others), Application (Therapeutic Applications, Diagnostic Applications, and Research Applications), End-User (Hospitals, Research Institutes, and Others)

The Europe monoclonal antibodies market is expected to reach US$ 61,019.8 million by 2028 from US$ 29,254.3 million in 2021. The market is estimated to grow at a CAGR of 11.1% from 2021-2028. According to the International AIDS Vaccine Initiative (IAVI) report, the development of mABs is one of the fastest-growing segments of biomedical research. For records, more than 50 mABs were licensed in the last six years, and in 2019, seven of the ten best-selling novel drugs for cancer and autoimmune diseases were mABs. Further, with the growing number of noncommunicable and infectious diseases, mABs can be an effective treatment; leading to increased demand for such products. For example, mABs sales are predominant in Europe. As the percentage of mABs in the development pipeline increases, more mABs will enter the market, and the disparity in access between high-income countries and others will worsen. Furthermore, a few combinations of mABs are also being developed to address many diseases, including chronic infections and cancer. Moreover, several counties are taking significant initiatives to shorten the regulatory process for mABs effective for treating chronic diseases. For records, in early 2019, the CFDA approved three mABs from domestic developers and ten mABs from multinational pharmaceutical companies. Such factors are stimulating the uptake of mABs, aiding the market significantly.

Based on source, the Monoclonal Antibodies (mAbs) market is segmented into human, humanized, chimeric, and murine. In 2020, the human segment accounted for the highest share, moreover the same segment is expected to grow at a CAGR of 12.7% in the forecast period.

Many European countries have accounted for more patients per day now than during the first wave of COVID-19 earlier this year. Lockdowns are reintroduced in the UK, Spain, Italy, and Ireland, as per the European Centre for Disease Prevention and Control (ECDC). Due to the second wave of the COVID-19 crisis, the governments of many nations are heading toward increasing testing capacity. Countries such as Italy, Spain, and France have recorded the maximum number of cases and deaths. The rising number of COVID-19 cases increased the demand for diagnostic tests from its healthcare system. In December 2021, Pfizer and BioNTech announced that the companies would amend the clinical safety study while evaluating the safety, tolerability, and immunogenicity of the Pfizer-BioNTech COVID-19 vaccine in children from 6 months to under 5 years of age.

The overall Europe monoclonal antibodies market size has been derived using both primary and secondary sources. To begin the research process, exhaustive secondary research has been conducted using internal and external sources to obtain qualitative and quantitative information related to the market. The process also serves the purpose of obtaining an overview and forecast for the Europe monoclonal antibodies market with respect to all the segments pertaining to the region. Also, multiple primary interviews have been conducted with industry participants and commentators to validate the data, as well as to gain more analytical insights into the topic. Participants of this process include industry experts such as VPs, business development managers, market intelligence managers, and national sales managers, along with external consultants such as valuation experts, research analysts, and key opinion leaders, specializing in the Europe monoclonal antibodies market. Companies adopt a few strategies, such as mergers and acquisitions and market initiatives, which promotes market growth. Novartis AG, Pfizer Inc., GlaxoSmithKline plc., Amgen Inc., DAIICHI SANKYO COMPANY, LIMITED, F. Hoffmann-La Roche Ltd., AstraZeneca, Eli Lilly and Company, Bayer AG, and Bristol-Myers Squibb Company are among the major players operating in the market.

Reasons to Buy

Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Europe monoclonal antibodies market.
Highlights key business priorities in order to assist companies to realign their business strategies.
The key findings and recommendations highlight crucial progressive industry trends in the Europe monoclonal antibodies market, thereby allowing players across the value chain to develop effective long-term strategies.
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
Scrutinize in-depth global market trends and outlook coupled with the factors driving the market, as well as those hindering it.
Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.